Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
24 results
D3.344 - Biological therapy for severe chronic spontaneous urticaria associated with autoimmune atrophic gastritis
D3.348 - A Case of 19p13.3 Microdeletion
D3.349 - Evaluation of natural killer cells in female infertility
D3.351 - Characterization of peanut roasting-enhanced Ara h 2 - Ara h 1 complexes
D3.345 - Blood Dendritic Cell Antigen 3-Positive Dendritic Cells Attenuate Th2 Responses in Allergic Rhinitis and Chronic Rhinosinusitis
D3.346 - Impact of local craniocerebral hypothermia on inflammatory cytokine production in ischemic stroke
D3.347 - AllergoOncology: a systematic review of the impact of glycosylation on IgE antibody structure function and mechanisms of disease
D3.350 - Monocytic myeloid-derived suppressor cells (M-MDSCs) increase the expression of TIGIT on γδ T cells
D3.353 - An EAACI Task Force Scoping Review: Human Monocytes and Macrophages in Allergy – Implications for AllergoOncology
D3.354 - Selective IgE deficiency in children: its role in autoimmunity
D3.355 - Decoupling of total IgE and peripheral blood eosinophilia in pancreatic ductal adenocarcinoma: preliminary study
D3.356 - Unconventional T cells in leukocyte adhesion deficiency I (LAD-I)
D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria
D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117
D2.354 - Questionnaire survey of new treatments for atopic dermatitis
D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria
D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria
D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience
D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download